Datapoint: Pfizer Inks Biohaven Deal

Pfizer this week unveiled a $11.6 billion deal to acquire Biohaven, the biotech known for its migraine drug Nurtec ODT. The oral CGRP inhibitor can be used to both treat and prevent migraines. For the treatment of migraines, Nurtec ODT holds covered or better status for 88% of all insured lives under the pharmacy benefit. Other oral therapies in the growing migraine space include two AbbVie drugs, Ubrelvy (86% covered or better status) and Qulipta (56%).

SOURCE: MMIT Analytics, as of 5/11/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 26

Datapoint: J&J Sees Potential Stelara Rival in Alvotech-Teva Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 25

Datapoint: Ohio Counties Offer the Most Medicare Advantage Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 24

Datapoint: Dupixent Scores First-in-Class EoE Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today